$BRTX
BioRestorative Therapies, Inc. Stock $brtx

$brtx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224044763 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$233.6K	$30.70K
YoY Change		660.91%	5.86%
Cost Of Revenue		$18.24K
YoY Change
Gross Profit		$215.4K	$30.70K
YoY Change		601.49%
Gross Profit Margin		92.19%	100.0%
Selling, General & Admin		$1.182M	$2.260M
YoY Change		-47.68%	-38.07%
% of Gross Profit		549.0%	7361.56%
Research & Development		$1.320M	$874.8K
YoY Change		50.89%	-11.56%
% of Gross Profit		612.95%	2849.59%
Depreciation & Amortization		$48.27K	$40.00K
YoY Change		20.68%	28.12%
% of Gross Profit		22.41%	130.29%
Operating Expenses		$2.502M	$3.135M
YoY Change		-20.18%	-32.41%
Operating Profit		-$2.287M	-$3.104M
YoY Change		-26.33%	-32.65%
Interest Expense		$1.195M	$60.00K
YoY Change		1891.68%	108.04%
% of Operating Profit
Other Income/Expense, Net		$1.196M	$179.0K
YoY Change		568.1%	-487.97%
Pretax Income		-$1.091M	-$2.930M
YoY Change		-62.75%	-37.07%
Income Tax
% Of Pretax Income
Net Earnings		-$1.091M	-$2.925M
YoY Change		-62.69%	-37.16%
Net Earnings / Revenue		-467.22%	-9529.29%
Basic Earnings Per Share		-$0.13	-$0.64
Diluted Earnings Per Share		-$0.13	-$0.64
COMMON SHARES
Basic Shares Outstanding	6.920M shares	6.920M shares	4.668M shares
Diluted Shares Outstanding		8.121M shares	4.571M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.09M	$12.24M
YoY Change	6.93%	-25.76%
Cash & Equivalents	$1.489M	$2.437M
Short-Term Investments	$11.60M	$9.800M
Other Short-Term Assets	$256.1K	$330.0K
YoY Change	-22.4%	-7.32%
Inventory
Prepaid Expenses
Receivables	$165.0K	$39.30K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$13.51M	$12.60M
YoY Change	7.18%	-25.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$378.4K	$306.3K
YoY Change	23.55%	32.42%
Goodwill
YoY Change
Intangibles	$646.4K	$736.1K
YoY Change	-12.19%	38.81%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.065M	$1.197M
YoY Change	-11.08%	15.96%
TOTAL ASSETS
Total Short-Term Assets	$13.51M	$12.60M
Total Long-Term Assets	$1.065M	$1.197M
Total Assets	$14.57M	$13.80M
YoY Change	5.6%	-22.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$401.4K	$227.4K
YoY Change	76.54%	-51.47%
Accrued Expenses	$682.2K	$549.0K
YoY Change	24.28%	378.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.582M	$932.6K
YoY Change	391.25%	30.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$40.00K
YoY Change		-79.87%
Total Long-Term Liabilities	$0.00	$40.00K
YoY Change	-100.0%	-79.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.582M	$932.6K
Total Long-Term Liabilities	$0.00	$40.00K
Total Liabilities	$4.582M	$975.0K
YoY Change	369.89%	6.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$154.0M	-$164.2M
YoY Change	-6.2%	10.75%
Common Stock	$692.00	$468.00
YoY Change	47.86%	28.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.992M	$12.83M
YoY Change
Total Liabilities & Shareholders Equity	$14.57M	$13.80M
YoY Change	5.6%	-22.99%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$1.091M	-$2.925M
YoY Change	-62.69%	-37.16%
Depreciation, Depletion And Amortization	$48.27K	$40.00K
YoY Change	20.68%	28.12%
Cash From Operating Activities	-$1.700M	-$1.180M
YoY Change	44.03%	-18.71%
INVESTING ACTIVITIES
Capital Expenditures	$58.46K	$10.00K
YoY Change	484.6%	-59.37%
Acquisitions
YoY Change
Other Investing Activities	$995.2K	-$10.00K
YoY Change	-10052.2%	-99.9%
Cash From Investing Activities	$936.8K	-$20.00K
YoY Change	-4783.75%	-99.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	1.860M
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-1.700M	-1.180M
Cash From Investing Activities	936.8K	-20.00K
Cash From Financing Activities	0.000	1.860M
Net Change In Cash	-762.8K	660.0K
YoY Change	-215.58%	-105.81%
FREE CASH FLOW
Cash From Operating Activities	-$1.700M	-$1.180M
Capital Expenditures	$58.46K	$10.00K
Free Cash Flow	-$1.758M	-$1.190M
YoY Change	47.73%	-19.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	BRTX	Grant Income GrantIncome		usd
	dei	Amendment Flag AmendmentFlag	false
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37603
	dei	Entity Registrant Name EntityRegistrantName	BIORESTORATIVE THERAPIES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-1341024
	dei	Entity Address Address Line1 EntityAddressAddressLine1	40 Marcus Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Melville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11747
	dei	City Area Code CityAreaCode	(631)
	dei	Local Phone Number LocalPhoneNumber	760-8100
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	BRTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Bankruptcy Proceedings Reporting Current EntityBankruptcyProceedingsReportingCurrent	true
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1489444	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	884377	usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11598417	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	10181618	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	165000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19300	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	233697	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	305231	usd
CY2024Q3	us-gaap	Assets Assets	14573451	usd
CY2023Q4	us-gaap	Assets Assets	12611720	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	401379	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	189389	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	42414	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	162317	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2607345	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001505497
CY2023Q3	BRTX	Gain On Exchange Of Warrants GainOnExchangeOfWarrants		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	126500	usd
	us-gaap	Operating Expenses OperatingExpenses	12126592	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12000092	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	176070	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	566	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33951	usd
CY2024Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1036464	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	7693753	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1195577	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7872704	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.00
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12324766	shares
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
	BRTX	Grant Income GrantIncome		usd
CY2024Q3	BRTX	Gain On Exchange Of Warrants GainOnExchangeOfWarrants		usd
	BRTX	Gain On Exchange Of Warrants GainOnExchangeOfWarrants		usd
CY2024Q2	BRTX	Stock Issued During Period Value Common Stock Issued In Connection With Abeyance Shares StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
	BRTX	Gain On Exchange Of Warrants GainOnExchangeOfWarrants		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	BRTX	Proceeds From Exchange And Issuance Of Warrants Net1 ProceedsFromExchangeAndIssuanceOfWarrantsNet1		usd
	BRTX	Payments For Proceeds From Deferred Offering Costs PaymentsForProceedsFromDeferredOfferingCosts		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	BRTX	Issuance Of Common Stock Held In Abeyance IssuanceOfCommonStockHeldInAbeyance		usd
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
	dei	Document Type DocumentType	10-Q
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6919919	shares
CY2024Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	22381	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	13508939	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	11390526	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	378434	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	356055	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39697	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	151447	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	646381	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	713692	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	682237	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	711686	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3455505	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1543953	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4581535	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2607345	usd
CY2024Q3	us-gaap	Liabilities Liabilities	4581535	usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	13982	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	13982	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6919919	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6919919	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4706917	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4706917	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	692	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	471	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164019809	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	156689256	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-154042567	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-146699334	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	9991916	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10004375	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14573451	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12611720	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	233600	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30700	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	357700	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18243	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24733	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	215357	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	30700	usd
	us-gaap	Gross Profit GrossProfit	332967	usd
	us-gaap	Gross Profit GrossProfit	126500	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1320030	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	809824	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3690495	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2944460	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1182320	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2325319	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5507524	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9182132	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	2502350	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	3135143	usd
	us-gaap	Operating Expenses OperatingExpenses	9198019	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2286993	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3104443	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8865052	usd
CY2024Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	158547	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	61667	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	497089	usd
CY2023Q3	BRTX	Grant Income GrantIncome	83333	usd
	BRTX	Grant Income GrantIncome	83333	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	150498	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	150423	usd
	BRTX	Gain On Exchange Of Warrants GainOnExchangeOfWarrants	1711698	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-837466	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3476556	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1521819	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3886382	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1091416	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	4768261	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7343233	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8113710	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.00
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8121499	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4570843	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7643437	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4061975	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8121499	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7643437	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4061975	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10004375	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4742243	usd
CY2024Q1	BRTX	Stock Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding	-48410	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	985038	usd
CY2024Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1043336	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2223255	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	14503327	usd
CY2024Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	324322	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-4028562	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	10799087	usd
CY2024Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	284245	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1091416	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	9991916	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10290339	usd
CY2023Q1	BRTX	Stock Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding	-39308	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1188070	usd
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2190428	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7172572	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6456957	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1164134	usd
CY2023Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	321534	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	411710	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5709399	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2644936	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2644936	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1164134	usd
CY2023Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	329570	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1853990	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	4768261	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	4768261	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	10760891	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	10760891	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3351580	shares
CY2024Q1	BRTX	Shares Held In Abeyance SharesHeldInAbeyance	1201580	shares
	us-gaap	Net Income Loss NetIncomeLoss	-7343233	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8113710	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	138687	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	123022	usd
	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	492476	usd
	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	166866	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2636941	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6318562	usd
	BRTX	Noncash Lease Expense NoncashLeaseExpense	111750	usd
	BRTX	Noncash Lease Expense NoncashLeaseExpense	87034	usd
	BRTX	Gain On Exchange Of Warrants GainOnExchangeOfWarrants	1711698	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-837466	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3476556	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	145700	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23300	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-23124	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-37151	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	211990	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	56453	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-29449	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	418882	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-119903	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-102921	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5882501	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4842249	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	17370243	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	18089372	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	18294566	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	14651512	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	93755	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	101019	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1018078	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3336841	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	411710	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1853990	usd
	BRTX	Proceeds From Exchange And Issuance Of Warrants Net1 ProceedsFromExchangeAndIssuanceOfWarrantsNet1	7528027	usd
	BRTX	Payments For Proceeds From Deferred Offering Costs PaymentsForProceedsFromDeferredOfferingCosts	22381	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7505646	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2265700	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	605067	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	760292	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	884377	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1676577	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1489444	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2436869	usd
	BRTX	Issuance Of Common Stock Held In Abeyance IssuanceOfCommonStockHeldInAbeyance	15	usd
	BRTX	Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding	48410	usd
	BRTX	Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding	39308	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	8123391	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	595364	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7300000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5900000	usd
CY2024Q3	BRTX	Working Capital WorkingCapital	8900000	usd
	BRTX	Proceeds From Warrant Exercises Net ProceedsFromWarrantExercisesNet	7500000	usd
	BRTX	Proceeds From Warrant Exercises Net ProceedsFromWarrantExercisesNet	7500000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z420wGSy4mo8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_863_zunsPzAXRzLe">Reclassifications </span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain prior period statements of operations, changes in stockholders’ equity and cash flows amounts have been reclassified to conform to the Company’s fiscal 2024 presentation. These reclassifications have no impact on the Company’s previously reported net (loss) income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1220350	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	604226	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zFSeTI4aDvH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_861_zCgSf3grvMm">Customer and Revenue Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the Company’s contract service revenue is derived from one customer. Additionally, all of the Company’s product sales revenue is derived from one customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Deferred Costs DeferredCosts	8333	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	0	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	233600	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30700	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	357700	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	126500	usd
CY2024Q3	BRTX	Shares Held In Abeyance SharesHeldInAbeyance	1201580	shares
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8752270	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8752270	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7753923	shares
CY2024Q3	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	584250	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	638000	usd
CY2024Q3	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	97987	usd
CY2023Q4	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	73686	usd
CY2024Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	682237	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	711686	usd
CY2024Q3	BRTX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingIntrinsicValue	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.77
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1466892	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1934716	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.45
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3401608	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.60
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2351081	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.03
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M24D
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	284245	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1493704	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2636941	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6318562	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1060129	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M20D
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	284245	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1493704	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2636941	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6318562	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
	us-gaap	Operating Lease Cost OperatingLeaseCost	129795	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	126021	usd
	us-gaap	Lease Cost LeaseCost	129795	usd
	us-gaap	Lease Cost LeaseCost	126021	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	129795	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	126021	usd
	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	119903	usd
	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	102921	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39697	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	154726	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	42414	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	156310	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42414	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	43265	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	43265	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	851	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	42414	usd
CY2024Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	2189420	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1543953	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2189420	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1115334	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-837466	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3455505	usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11598417	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	10181618	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3455505	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1543953	usd

Files In Submission

Name	View Source	Status
0001493152-24-044763-index-headers.html	Edgar Link	pending
0001493152-24-044763-index.html	Edgar Link	pending
0001493152-24-044763.txt	Edgar Link	pending
0001493152-24-044763-xbrl.zip	Edgar Link	pending
brtx-20240930.xsd	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
brtx-20240930_cal.xml	Edgar Link	unprocessable
brtx-20240930_def.xml	Edgar Link	unprocessable
brtx-20240930_lab.xml	Edgar Link	unprocessable
brtx-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRTX
BioRestorative Therapies, Inc. Stock $brtx

2024 Q4 Form 10-Q Financial Statement

#000149315224044763 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX BioRestorative Therapies, Inc. Stock $brtx

2024 Q4 Form 10-Q Financial Statement

#000149315224044763 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX
BioRestorative Therapies, Inc. Stock $brtx